Patents by Inventor John Sigurd Svendsen
John Sigurd Svendsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338609Abstract: The present invention provides a formulation comprising a biodegradable polyester compounded with a compound of Formula (I): AA-AA-AA-X-Y. The invention further provides methods of making these formulations, medical devices such as sutures comprising said formulations and methods of making said devices.Type: ApplicationFiled: June 14, 2021Publication date: October 26, 2023Applicant: AMICOAT ASInventors: Wenche Stensen, John Sigurd Svendsen
-
Publication number: 20230233736Abstract: The present invention provides a controlled release formulation comprising a silicone substrate which comprises a compound of Formula (I): AA-AA-AA-X—Y. The invention further provides methods of making these formulations, medical devices such as dressings incorporating said formulations and medical uses thereof.Type: ApplicationFiled: June 14, 2021Publication date: July 27, 2023Applicant: AMICOAT ASInventors: Andreas Spiegelberg, Wenche Stensen, John Sigurd Svendsen
-
Patent number: 10927106Abstract: The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.Type: GrantFiled: October 12, 2017Date of Patent: February 23, 2021Assignee: PHARMASUM THERAPEUTICS ASInventors: John Sigurd Svendsen, Wenche Stensen, Roderick Alan Porter
-
Publication number: 20190375742Abstract: The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.Type: ApplicationFiled: October 12, 2017Publication date: December 12, 2019Inventors: John Sigurd Svendsen, Wenche Stensen, Roderick Alan Porter
-
Patent number: 10287320Abstract: The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumor (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.Type: GrantFiled: February 4, 2015Date of Patent: May 14, 2019Assignee: Universitetet i Tromsø—Norges Arktiske UniversitInventors: John Sigurd Svendsen, Øystein Rekdal, Johannes Eksteen
-
Publication number: 20170073372Abstract: The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumour (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.Type: ApplicationFiled: February 4, 2015Publication date: March 16, 2017Inventors: John Sigurd SVENDSEN, Oystein REKDAL, Johannes EKSTEEN
-
Patent number: 9556223Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumor or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.Type: GrantFiled: October 2, 2009Date of Patent: January 31, 2017Assignee: LYTIX BIOPHARMA ASInventors: Wenche Stensen, Frederick Alan Leeson, Øystein Rekdal, John Sigurd Svendsen
-
Publication number: 20160176923Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.Type: ApplicationFiled: December 14, 2015Publication date: June 23, 2016Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9241968Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.Type: GrantFiled: September 11, 2009Date of Patent: January 26, 2016Assignee: Lytix Biopharma ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9212202Abstract: The present invention relates to a method of improving the resistance of a peptide or peptidomimetic to degradation by trypsin which comprises incorporating into said peptide or peptidomimetic a C-terminal capping group of formula (I): X—Y—Z (I) wherein X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb,- and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb, may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z. moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.Type: GrantFiled: December 22, 2008Date of Patent: December 15, 2015Assignee: Lytix Biopharma ASInventors: Wenche Stensen, Oystein Rekdal, John Sigurd Svendsen
-
Patent number: 9115169Abstract: The invention provides a method of treating tumors by adminstering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length, which incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and containing no more than 2 polar functional groups, in which the bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and in which the molecule further has at least two more cationic than anionic moieties.Type: GrantFiled: September 22, 2011Date of Patent: August 25, 2015Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Patent number: 9109048Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: GrantFiled: August 14, 2012Date of Patent: August 18, 2015Assignee: LYTIX BIOPHARMA ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
-
Patent number: 9085608Abstract: The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, —b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.Type: GrantFiled: October 2, 2009Date of Patent: July 21, 2015Assignee: LYTIX BIOPHARMA ASInventors: Wenche Stensen, Frederick Alan Leeson, Stig Olov Magnus Engqvist, Trond Flægstad, Øystein Rekdal, John Sigurd Svendsen
-
Publication number: 20150018311Abstract: The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to C? is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal cappinType: ApplicationFiled: January 8, 2013Publication date: January 15, 2015Applicant: University of TromsøInventors: Tore Lejon, John Sigurd Svendsen, Alexey Gorovoy, Olga Gozhina
-
Publication number: 20140037657Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: ApplicationFiled: August 14, 2012Publication date: February 6, 2014Applicant: LYTIX BIOPHARMA ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjornsson, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 8598114Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-X—Y—Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb— and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.Type: GrantFiled: December 22, 2008Date of Patent: December 3, 2013Assignee: Lytix Biopharma ASInventors: Wenche Stensen, Bengt Erick Haug, Oystein Rekdal, John Sigurd Svendsen
-
Patent number: 8283315Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: GrantFiled: March 21, 2007Date of Patent: October 9, 2012Assignee: Lytix Biopharma ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
-
Publication number: 20120108520Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: ApplicationFiled: September 22, 2011Publication date: May 3, 2012Applicant: LYTIX BIOPHARMA ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Patent number: 8143211Abstract: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.Type: GrantFiled: July 2, 2008Date of Patent: March 27, 2012Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Øystein Rekdal, Baldur Sveinbjørnsson, Lars Vorland
-
Publication number: 20110318364Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.Type: ApplicationFiled: September 11, 2009Publication date: December 29, 2011Applicant: LYTIX BIOPHARMA ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal